What question did this study set out to answer?

The aim is to explore how ZRANB1 influences MYCN stability in neuroblastoma and its role as a therapeutic target.

April 10, 2026Open Access

ZRANB1 depletion inhibits neuroblastoma progression by destabilizing MYCN through EZH2-mediated deubiquitination

Key Points

The aim is to explore how ZRANB1 influences MYCN stability in neuroblastoma and its role as a therapeutic target.
Identified ZRANB1 as a deubiquitinase.
Examined the relationship between ZRANB1, EZH2, and MYCN.
Analyzed MYCN stability in MYCN-amplified neuroblastoma cells.
ZRANB1 depletion led to increased destabilization of MYCN.
EZH2 is identified as a regulatory intermediary in this process.
Establishing ZRANB1 as a therapeutic target shows potential for neuroblastoma treatment.

Abstract

This study identifies ZRANB1 as an upstream deubiquitinase that stabilizes EZH2, thereby indirectly maintaining MYCN stability in MYCN-amplified neuroblastoma. These findings establish a ZRANB1-EZH2-MYCN regulatory axis and highlight ZRANB1 as a promising therapeutic target in MYCN-amplified NB.

Bookmark

View Full Paper

Bookmark

View Full Paper

ZRANB1 depletion inhibits neuroblastoma progression by destabilizing MYCN through EZH2-mediated deubiquitination

Key Points

Abstract

Cite This Study